8-K: BioCardia Announces Data Freeze in CardiAMP Heart Failure Trial, Results to be Presented at ACC 2025

BioCardia completes data verification and freezes primary outcomes data for its Phase 3 CardiAMP HF study, with results slated for presentation at the American College of Cardiology 2025 Scientific Sessions.

Summary

• BioCardia, Inc. has completed source data verification and frozen primary outcomes data from its Phase 3 CardiAMP HF study.
• The study investigates the use of autologous minimally invasive cell therapy for ischemic heart failure with reduced ejection fraction (HFrEF).
• Data from 115 randomized patients has been transferred to the Statistical Data Analysis Center for analysis.
• The results are scheduled to be presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago on March 30, 2025.
• BioCardia believes this data represents the largest ischemic HFrEF patient cohort studied in a randomized trial of an autologous cell therapy.
• The trial uses a precision medicine approach to identify patients likely to respond to therapy based on their cells.
• The clinical study aims to provide evidence supporting the safety and effectiveness of CardiAMP cell therapy for future approvals in the United States and Japan.
• The results are also expected to support the safety and effectiveness of the Helix biotherapeutic delivery system for standalone approval.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the completion of a key milestone in the CardiAMP HF study and the anticipation of presenting results at a major conference. However, the presence of forward-looking statements and associated risks tempers the overall optimism.

Positives

• Completion of source data verification and freezing of primary outcomes data in the Phase 3 CardiAMP HF study is a significant milestone.
• Presentation of the results at the American College of Cardiology (ACC) 2025 Scientific Sessions provides a platform for visibility.
• FDA Breakthrough designation for CardiAMP Cell Therapy suggests potential for expedited regulatory review.
• The study is supported by the Maryland Stem Cell Research Fund and reimbursed by Centers for Medicare and Medicaid Services (CMS), indicating external validation and financial support.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from the forward-looking statements.
• The company's Form 10-K filed with the Securities and Exchange Commission on March 27, 2024, under the caption titled Risk Factors, and in our subsequently filed Quarterly Reports on Form 10-Q, contains additional factors that could materially affect actual results.

Future Outlook

The company anticipates presenting the results of the CardiAMP HF study at the ACC 2025 Scientific Sessions and expects the data to support future regulatory approvals in the United States and Japan, as well as standalone approval for the Helix biotherapeutic delivery system.

Management Comments

• Peter Altman, PhD, BioCardia President and CEO, stated that the clinical study is intended to provide evidence supporting the safety and effectiveness of the CardiAMP cell therapy system for future approvals in the United States and Japan.
• Peter Altman, PhD, BioCardia President and CEO, stated that the results are also expected to support the safety and effectiveness of the Helix biotherapeutic delivery system for standalone approval.

Industry Context

The announcement positions BioCardia as a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, particularly in the treatment of ischemic heart failure. The focus on autologous cell therapy and precision medicine aligns with current trends in regenerative medicine and personalized healthcare.

Comparison to Industry Standards

• The press release states that the data represents the largest ischemic HFrEF patient cohort studied in a randomized trial of an autologous cell therapy, suggesting a leading position in this specific area.
• Other companies in the cell therapy space include Vericel, Mesoblast, and Athersys, but their specific focus and clinical trial designs may differ from BioCardia's CardiAMP study.

Stakeholder Impact

• Positive results from the CardiAMP HF study could benefit patients with ischemic heart failure and reduced ejection fraction (HFrEF).
• Successful regulatory approvals could increase shareholder value.
• The company's employees may benefit from the continued development and commercialization of its products.

Next Steps

• Presentation of the CardiAMP HF study results at the American College of Cardiology (ACC) 2025 Scientific Sessions on March 30, 2025.
• Analysis of the data by the Statistical Data Analysis Center core laboratory.
• Potential regulatory submissions in the United States and Japan based on the study results.
• Pursuit of standalone approval for the Helix biotherapeutic delivery system.

Key Dates